Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019

• Published in: Alzheimer's & dementia Vol. 17; no. 4; pp. 696 - 701
• Main Authors: Knopman, David S., Jones, David T., Greicius, Michael D.
• Format: Journal Article
• Language: English
• Published: United States 01.04.2021

Aducanumab recently underwent two large phase III clinical trials that were stopped prematurely by the sponsor Biogen. One trial was trending positive while the other showed no benefits from aducanumab. Post hoc analyses led the sponsor to assert that there was a sufficient efficacy signal to justif...